AI Startup Exchange
Strategic Investment: Ribocure (06938.HK) Debuts on HKEX Main Board
DABANC is proud to announce **Ribocure Pharmaceuticals (06938.HK)**’s successful listing on the Hong Kong Stock Exchange on January 9, 2026. As a pioneer in the siRNA sector, Ribocure’s IPO marks a significant step for RNA therapeutics in China. DABANC, as an early strategic investor, continues to support transformative life sciences technologies that address critical clinical needs.
We are proud to announce a significant achievement within DABANC’s healthcare strategic investment. On January 9, 2026, Ribocure Pharmaceuticals (06938.HK) officially listed on the Main Board of the Hong Kong Stock Exchange.
As a pioneer in the siRNA (small interfering RNA) sector, Ribocure’s listing represents a pivotal moment for the capitalization of innovative RNA therapeutics in China. DABANC identified the transformative potential of Ribocure’s technology long before this market milestone.
This successful IPO not only fuels new momentum for the industry but also validates DABANC's investment thesis: backing the fundamental infrastructure of life sciences to solve unmet clinical needs.
